# ZAI LAB LIMITED (ZLAB) · Edgar & Edgarette company card

> Zai Lab Limited (ZLAB) grew revenue 15.3% in FY2025 to $460 million, operating margin -49.9% against a -3.8% median for pharmaceutical preparations, equity 61.0% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1704292 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ZLAB) · [JSON](https://www.pops4.com/boards/company/ZLAB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $460M |
| Revenue growth, 1 year | 15.3% |
| Revenue growth per year | 33.6% |
| Operating margin | -49.9% (prior year -70.7%) |
| Net margin | -38.1% |
| Operating cash flow | −$151M |
| Capital spending | $8M |
| Free cash flow | −$159M |
| Cash | $680M |
| Long-term debt | — |
| Total assets | $1.2B |
| Total equity | $716M |
| Equity ÷ assets | 61.0% |
| Return on equity | -24.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -3.61 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.36 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -49.9% in FY2025
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $460.2M (FY2025). Experience: revenue up 15.3% on the year, up 33.6% a year over 4 years; operating margin -49.9%, up from -70.7%. Soundness: equity 61.0% of assets, return on equity -24.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $454.4M and $668.5M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $412.2M to $739.9M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -49.9% against a -3.8% median; growth 15.3% against 13.7%.

Range logged 2026-10-26, receipt 94721dfcd649587e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-05-21 ([filing](https://www.sec.gov/Archives/edgar/data/1704292/000162828026037387/0001628280-26-037387-index.htm))

## Recent filings

- 10-Q · filed 2026-11-05 · [filing](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070521/0001628280-26-070521-index.htm)
- 8-K · filed 2026-11-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1704292/000162828026070517/0001628280-26-070517-index.htm)
- 8-K · filed 2026-10-23 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1704292/000162828026066969/0001628280-26-066969-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/0001628280-26-053793-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/0001628280-26-053791-index.htm)
- 8-K · filed 2026-06-17 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1704292/000162828026043869/0001628280-26-043869-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001704292.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1704292

## Cite

POPS4, Edgar & Edgarette: ZAI LAB LIMITED (ZLAB) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ZLAB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

